Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Double-blind, Parallel-group, Active-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of LXI-15028 Comparing With Esomeprazole in the Treatment of Erosive Esophagitis in Chinese Patients for up to 8 Weeks

NCT03615677 is registered in ClinicalTrials.gov with Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. as lead sponsor.

NCT NCT03615677
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03615677 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Double-blind, Parallel-group, Active-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of LXI-15028 Comparing With Esomeprazole in the Treatment of Erosive Esophagitis in Chinese Patients for up to 8 Weeks
Lead sponsor
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
October 24, 2018
Completion date
October 18, 2019
Enrollment
261 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

erosive esophagitis (ee)